Craig C. Hopkinson - 30 Jan 2025 Form 4 Insider Report for Alkermes plc. (ALKS)

Role
EVP R&D, Chief Medical Officer
Signature
/s/ Shantale Greenson, attorney-in-fact for Craig C. Hopkinson
Issuer symbol
ALKS
Transactions as of
30 Jan 2025
Net transactions value
-$1,065,245
Form type
4
Filing time
31 Jan 2025, 20:42:16 UTC
Previous filing
09 Dec 2024
Next filing
07 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALKS Ordinary Shares Options Exercise $583,995 +29,156 +61% $20.03 76,732 30 Jan 2025 Direct F1
transaction ALKS Ordinary Shares Options Exercise $514,231 +26,589 +35% $19.34 103,321 30 Jan 2025 Direct F1
transaction ALKS Ordinary Shares Options Exercise $578,898 +23,542 +23% $24.59 126,863 30 Jan 2025 Direct F1
transaction ALKS Ordinary Shares Options Exercise $492,013 +18,345 +14% $26.82 145,208 30 Jan 2025 Direct F1
transaction ALKS Ordinary Shares Sale $3,234,382 -100,918 -69% $32.05 44,290 30 Jan 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALKS Employee Stock Option (Right to Buy) Options Exercise $0 -29,156 -25% $0.000000 87,566 30 Jan 2025 Ordinary Shares 29,156 $20.03 Direct F1, F4
transaction ALKS Employee Stock Option (Right to Buy) Options Exercise $0 -26,589 -14% $0.000000 161,734 30 Jan 2025 Ordinary Shares 26,589 $19.34 Direct F1, F5
transaction ALKS Employee Stock Option (Right to Buy) Options Exercise $0 -23,542 -18% $0.000000 106,758 30 Jan 2025 Ordinary Shares 23,542 $24.59 Direct F1, F6
transaction ALKS Employee Stock Option (Right to Buy) Options Exercise $0 -18,345 -17% $0.000000 92,271 30 Jan 2025 Ordinary Shares 18,345 $26.82 Direct F1, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 This option exercise was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.
F2 This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 12/14/2023.
F3 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $32.00 to $32.17. Full information regarding the number of shares sold at each separate price can be provided to the issuer, any security holder of the issuer or the SEC staff upon request.
F4 These options are fully vested in accordance with their terms.
F5 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/22/2022.
F6 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/18/2023.
F7 Shares underlying the stock option vest and become exercisable in four equal annual installments commencing on 2/23/2024.